Literature DB >> 28834871

Bioinformatics analysis of gene expression profiling for identification of potential key genes among ischemic stroke.

Kaihua Zhai1, Xiangli Kong, Boyu Liu, Jiyu Lou.   

Abstract

This study aimed to identify the key differentially expressed genes (DEGs) following ischemic stroke (IS).The GSE22255 microarray dataset, which contains samples from peripheral blood mononuclear cells of 20 IS patients and 20 sex- and age-matched controls, was downloaded from the Gene Expression Omnibus. After data pre-processing, DEGs were identified using the Linear Models for Microarray Data package in R. The Search Tool for the Retrieval of Interacting Genes database was used to predict the interactions among the products of DEGs, and then Cytoscape software was used to visualize the protein-protein interaction (PPI) network. DEGs in the PPI network were then analyzed using the Database for Annotation, Visualization, and Integrated Discovery online software to predict their underlying functions through functional and pathway enrichment analyses.A total of 144 DEGs were identified in IS samples compared with control samples, including 75 upregulated and 69 downregulated genes. Genes with higher degrees in the PPI network included FOS (degree = 26), TP53 (degree = 22), JUN (degree = 20), EGR1 (degree = 18), JUNB (degree = 16), and ATF3 (degree = 15), and these genes may function in IS by interacting with each other (e.g., EGR1-JUN, EGR1-TP53, ATF3-FOS, and JUNB-FOS). Functional enrichment analysis indicated that the downregulated TP53 gene was enriched in immune response and protein targeting categories.ATF3 and EGR1 may have an important protective effect on IS, whereas FOS, JUN, and JUNB may be associated with the development of IS. In addition, TP53 may function as an indicator of poor prognosis for IS through its association with the immune response and protein targeting.

Entities:  

Mesh:

Year:  2017        PMID: 28834871      PMCID: PMC5571993          DOI: 10.1097/MD.0000000000007564

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Stroke (also called brain attack, cerebrovascular accident, or cerebrovascular insult) is the second most common cause of death worldwide, ranking only after heart disease.[ Stroke is characterized by symptoms such as inability to move or feel one side of the body, inability to speak, or understand problems and dizziness.[ Advanced age is one of the main risk factors for stroke. Approximately 95% of patients with stroke are over 45 years of age, and two-thirds of stroke cases happen in those older than 65 years of age.[ Ischemic stroke (IS) induced by lack of blood flow is one of the main types of stroke.[ In 2013, stroke accounts for 6.4 million deaths (12% of the total) worldwide, and approximately half of these deaths result from IS.[ Recent studies have shown that the deletion or downregulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene activates mechanistic target of rapamycin (mTOR) signaling[ or the PTEN/v-Akt murine thymoma viral oncogene homolog (Akt) pathway[ to protect against neuronal death after brain injury caused by oxygen and glucose deprivation (OGD) in IS patients. Kallikrein gene transfer has neuroprotective effects in IS patients by the promotion of glial cell migration and survival and suppression of apoptosis through the activation of the Akt–B-cell leukemia/lymphoma 2 (BCL2) signaling pathway and inhibition of oxidative stress.[ The 511C/T interleukin-1β (IL-1β) polymorphism plays roles in IS and myocardial infarction among young individuals and in the inflammatory response of mononuclear cells.[ The rs7193343-T sequence variant of the Zinc Finger Homeobox 3 (ZFHX3) gene on chromosome 16q22 is related to IS and cardioembolic stroke in an integrated analysis of 5 sets of stroke samples.[ However, despite all of this research, the mechanism underlying IS remains unclear. Atherosclerosis of the thoracic aorta is an independent risk factor for IS, and peripheral blood mononuclear cells (PBMCs) are of significance because blood-borne white blood cells, first polymorphonuclear cells and then mononuclear cells (i.e., PBMCs), respond to IS. Mononuclear cells can selectively migrate and infiltrate into ischemic brain tissue and then adhere to vascular endothelial cells, which is a main event in the development of atherosclerosis.[ In addition, this early cellular inflammation and its consequences may evolve into cerebral infarct and reperfusion injury. In addition, the tail and damage DNA in the PBMCs of IS patients was significantly higher than that in those of convalescent patients.[ Thus, PBMCs are frequently chosen to detect differentially expressed genes (DEGs) for the prediction of gene changes related to IS. In 2012, Krug et al[ performed microarray analysis in PBMCs from 20 IS patients and 20 matched controls and identified 580 DEGs. However, the interactions among gene products and the potential functions of these genes were not analyzed. In our study, the microarray data deposited by Krug et al[ were studied to further screen DEGs and analyze the protein–protein interaction (PPI) network of their products. Moreover, functions of DEGs in the PPI network were predicted by functional and pathway enrichment analyses. This study may provide new insights into therapeutic targets for IS.

Methods

Microarray data

The gene expression microarray data (GSE22255) deposited by Krug et al[ were downloaded from the National Center of Biotechnology Information (NCBI) Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/), which was based on the platform of the GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. GSE22255 included data on PBMCs from 20 IS patients (10 females and 10 males, mean age at examination, 60.2 ± 10.6 years) and 20 sex- and age-matched controls (10 females and 10 males, mean age at examination, 58.7 ± 11.0 years). All of the participants were adult Caucasians, and IS patients had only 1 stroke episode at least 6 months before blood collection. The controls did not have a family history of stroke. Individuals with active allergies or severe anemia were also excluded. The research by Krug et al[ was approved by the ethics committees of the participating institutions, and all subjects provided informed consent.

Data pre-processing and DEG screening

After the raw data were downloaded, the Affy package[ in Bioconductor was used for data pre-processing. Pre-processing included background correction, quantile normalization, and probe ID to gene symbol transformation. Probes were mapped to NCBI entrez genes using Gene ID converter.[ If there were multiple probes that corresponded to the same gene, their average value was taken as the final gene expression level. Then, the Linear Models for Microarray Data (limma) package in R was used to identify DEGs between IS and control samples. The cut-off criteria for DEGs were defined as a P < .05 and a |log2 fold change (FC)| > .3 because a P < .05 is commonly used for screening DEGs [ and the |log2 FC| > .3 combined P < .05 was used to control the number of DEGs within a manageable but useful range, not too many or too few.

Construction of the PPI network

The Search Tool for the Retrieval of Interacting Genes (STRING),[ a database that facilitates searching of both functional and physical interactions of proteins, was used to predict the interactions among the products of DEGs, with the default threshold of the combined score > .4 in STRING. Cytoscape software (http://www.cytoscape.org/), a standard tool for integrated analysis and visualization of biological networks, such as molecular interaction networks and biological pathways, with computer-based assistance, was used to visualize the PPI network.[ Cytoscape Core are available for layout, scripting, file formatting, and linking the network to databases with functional annotations.[ In addition, nodes and edges in the figures were used to represent large biological data in an easily interpretable manner. Nodes represent biological molecules and edges connect the nodes to indicate their relationship.[ The pivotal nodes in the PPI network were identified based on their connectivity degrees.

Functional and pathway enrichment analyses

GO analysis is dedicated to the functional study of large-scale transcriptomic or genomic data.[ The Kyoto Encyclopedia of Genes and Genomes (KEGG) database provides information on function of molecules or genes.[ The genes with their products included in the PPI network were subjected to the Database for Annotation, Visualization, and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov)[ algorithm to find significantly related biological processes and KEGG pathways. The thresholds were set at a P < .05 and an enriched gene count >2.[

Results

Identification of DEGs

After pre-processing, a total of 144 DEGs were identified in IS samples compared with control samples, including 75 upregulated genes [e.g., FOS, JUN, JUNB, early growth response protein 1 (EGR1), and activating transcription factor 3 (ATF3)] and 69 downregulated genes [e.g., tumor-suppressor protein p53 (TP53)].

PPI network analysis

The PPI network for DEGs is shown in Fig. 1, which has 59 nodes and 212 interactions. The top 20 nodes with higher degrees are listed in Table 1, including FOS (degree = 26), TP53 (degree = 22), JUN (degree = 20), EGR1 (degree = 18), JUNB (degree = 16), and ATF3 (degree = 15). In particular, EGR1, JUNB, and ATF3 could interact with each other and also had interactions with other proteins (e.g., EGR1-JUN, EGR1-FOS, EGR1-TP53, ATF3-FOS, ATF3-JUN, JUNB-JUN, and JUNB-FOS).
Figure 1

The protein–protein interaction (PPI) network for the differentially expressed genes (DEGs) in ischemic stroke (IS) samples. Red and green nodes represent upregulated genes and downregulated genes, respectively. The nodes with a deeper color had larger |log2 fold change (FC)| values.

Table 1

The top 20 gene products with higher degrees in the protein–protein interaction network for the differentially expressed genes (DEGs).

The protein–protein interaction (PPI) network for the differentially expressed genes (DEGs) in ischemic stroke (IS) samples. Red and green nodes represent upregulated genes and downregulated genes, respectively. The nodes with a deeper color had larger |log2 fold change (FC)| values. The top 20 gene products with higher degrees in the protein–protein interaction network for the differentially expressed genes (DEGs).

Enrichment analysis for DEGs in the PPI network

DEGs in the PPI network were further subjected to DAVID software analysis to find significant biological processes and KEGG pathways. Functional enrichment analysis revealed that the upregulated genes were significantly enriched in response to the organic substance category (P = 1.86E-08, which involved EGR1, FOS, JUN, and JUNB), apoptosis (P = 2.54E-08, which involved JUN), and programmed cell death (P = 2.99E-08, which involved JUN) (Table 2). Moreover, these genes were mainly involved in the MAPK signaling pathway (P = 3.01E-04, which involved FOS and JUN), T cell receptor signaling pathway (P = 5.83E-04, which involved FOS and JUN), and cancer pathways (P = 3.04E-02, which involved FOS and JUN) (Table 3).
Table 2

The top 10 biological processes for both upregulated differentially expressed genes (DEGs) and downregulated DEGs in the protein–protein interaction (PPI) network.

Table 3

The pathways involved the upregulated genes in the protein–protein interaction (PPI) network.

The top 10 biological processes for both upregulated differentially expressed genes (DEGs) and downregulated DEGs in the protein–protein interaction (PPI) network. The pathways involved the upregulated genes in the protein–protein interaction (PPI) network. Furthermore, the downregulated genes were involved in immune responses (P = 5.80E-05, which involved TP53), protein targeting (P = 1.56E-03, which involved TP53) and mitochondrial depolarization regulation (P = 7.74E-03) (Table 2). However, no pathway was significantly enriched for the downregulated genes.

Discussion

In this study, a total of 144 DEGs were identified in IS samples compared with control samples, including 75 upregulated genes and 69 downregulated genes. FOS (degree = 26), TP53 (degree = 22), JUN (degree = 20), EGR1 (degree = 18), JUNB (degree = 16), and ATF3 (degree = 15) had higher degrees in the PPI network of the DEGs. Importantly, EGR1, JUNB, and ATF3 could interact with each other and also had interaction with other proteins (e.g., EGR1-JUN, EGR1-FOS, EGR1-TP53, ATF3-FOS, ATF3-JUN, JUNB-JUN, and JUNB-FOS). Thus, these genes might function in IS through such interactions. Moonlighting proteins are a subset of multifunctional proteins that have 2 or more different functions performed by 1 polypeptide chain.[ Our predicted hub genes in the PPI network such as ATF3, FOS, and JUN are reported to be moonlighting proteins in the Moonprot database[ and may be related to IS by regulating a variety of multifunctional mechanisms. ATF3 encodes a member of the activation transcription factor/adenosine 3′, 5′-monophosphate (cAMP) responsive element-binding (CREB) protein family.[ Because it exists in different isoforms and has many transcription factor binding sites, such as activation protein 1 (AP-1) and nuclear factor-kappa B (NF-κB), ATF3 plays a crucial role in cellular stress responses, wound healing, cell adhesion, oncogenesis, and multiple signal transduction pathways.[ Recently, ATF3 is found to be significantly overexpressed in brain ischemia. Its knockdown worsens the brain injury and inflammatory responses through activating the NF-κB signaling pathway, indicating that ATF3 may serve as a key protective regulator in ischemic injury.[ATF3 inhibits carboxyl-terminal modulator protein (CTMP) expression through binding to the ATF/cAMP/CREB site and CTMP siRNA treatment maintains ATF3 levels. Furthermore, the ATF3 to CTMP signaling cascade may be endogenously neuroprotective and assist in repair of ischemic brain injury.[ATF3 affects the pathways of caspase-dependent neuronal apoptotic signal transduction that are induced by reperfusion injury and focal cerebral ischemia.[ATF3 expression and synaptic activity promote resistance of hippocampal neurons to loss of synapses and acute dendrotoxicity, which contributes to functional restoration of neuronal networks after excitotoxic insults.[ Therefore, ATF3 may have an important protective effect in IS. FOS (including c-Fos, FosB, Fra1, and Fra2) and JUN (including c-Jun, JunB, and JunD), members of the AP-1 family, can dimerize in various combinations via a leucine zipper region.[ They have multiple biochemical functions, including cell proliferation, transformation, and apoptosis[, as well as responding to DNA damage.[ Pathway enrichment suggested that the upregulated FOS and JUN were enriched in the MAPK signaling pathway, the T cell receptor signaling pathway, and cancer pathways. It has been demonstrated that the MAPK-c-Jun N-terminal kinase (JNK) signaling pathway is involved in injury, and blocking this pathway prevents apoptosis in areas of aminoglycoside damage.[ Reportedly, the protease-resistant peptide of JNK can function as a neuroprotective agent for stroke through preventing c-Fos transcription and c-Jun activation.[ In the rat brain, after middle cerebral artery occlusion and a 2-hour reperfusion, the expression of FOS, brain-derived neurotrophic factor (BDNF), cyclooxygenase-2 (COX-2), and heat shock protein 70 (HSP70) are inhibited by magnesium sulphate, which has therapeutic potential.[ Furthermore, the mRNA expression of FOS and HSP70 is significantly repressed by hypothermia, which is associated with decreased lesion expansion in the process of acute focal ischemia.[ Together, these findings indicate that FOS, JUN, and JUNB might be associated with the development of IS. Functional enrichment analysis showed that upregulated EGR1 was enriched in response to the organic substances category. Previous studies have shown that EGR1 can regulate the transcriptional network in gliosis caused by ischemic injury.[EGR1 expression may protect against neuronal damage as well as ameliorate thrombosis and inflammation in stroke.[EGR1 may act as an important protective regulator in IS through its induction in response to organic substances. Functional enrichment analysis indicated that downregulated TP53 was enriched in the immune response and protein targeting categories. The Arg/Arg genotype of TP53 controls neuronal vulnerability to apoptosis and is a predictor of poor prognosis for stroke.[ Through preventing p53-mediated apoptosis in brain cells, activated protein C (APC) functions as a protector of the brain after ischemic injury.[ Thus, we suggest that similarly, TP53 functions as a predictor of poor prognosis for IS, through functions involving immune responses and protein targeting. In addition, it is worth noting that although we used the same GSE22255 dataset as that used in a study by Bi et al,[ we used different cut-off criteria for screening DEGs. Our threshold value was less restrictive than theirs to avoid a small number of DEGs being identified, which could limit the ensuing bioinformatics analysis, because only 27 DEGs were screened in their study. Moreover, we have constructed the PPI network to analyze the interrelationship among DEGs. However, there were still some limitations in the present study. First, although the PPI network and enrichment analyses for DEGs were performed, the prediction of transcription factors and miRNAs that regulate DEGs as well as a coexpression network analysis are still needed to potentially offer a more comprehensive insight into IS. Second, although the cut-off criteria of a P < .05 and |log2 (FC)| > .3 were appropriate and common for screening DEGs, a stricter threshold value is needed to screen for highly significant genes. However, with the above criteria, we only identified 144 DEGs, which is relatively few, and thus, we decided against using a stricter threshold value. Lastly, although we speculated that several genes, such as ATF3, EGR1, FOS, JUN, JUNB, and TP53, were closely associated with IS; further experiments should be performed to validate this. In conclusion, through bioinformatics analysis, a total of 144 DEGs were identified in IS samples compared with control samples. ATF3 and EGR1 might have an important protective effect on IS, whereas FOS, JUN, and JUNB might be associated with the development of the IS response. In addition, TP53 may function as a predictor of poor prognosis for IS through immune responses and protein targeting. However, these results should be confirmed by further experimental research.
  45 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Effects of Stroke on the Autonomic Nervous System.

Authors:  Anne M Dorrance; Greg Fink
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

3.  Mild hypothermia decreases the incidence of transient ADC reduction detected with diffusion MRI and expression of c-fos and hsp70 mRNA during acute focal ischemia in rats.

Authors:  A Mancuso; N Derugin; K Hara; F R Sharp; P R Weinstein
Journal:  Brain Res       Date:  2000-12-22       Impact factor: 3.252

Review 4.  Advances in the vascular pathophysiology of ischemic stroke.

Authors:  G J del Zoppo; J M Hallenbeck
Journal:  Thromb Res       Date:  2000-05-01       Impact factor: 3.944

5.  Identification of therapeutic targets of ischemic stroke with DNA microarray.

Authors:  B-L Bi; H-J Wang; H Bian; Z-T Tian
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-11       Impact factor: 3.507

6.  A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss.

Authors:  J Wang; T R Van De Water; C Bonny; F de Ribaupierre; J L Puel; A Zine
Journal:  J Neurosci       Date:  2003-09-17       Impact factor: 6.167

7.  Egr-1 regulates expression of the glial scar component phosphacan in astrocytes after experimental stroke.

Authors:  Heike Beck; Matthias Semisch; Carsten Culmsee; Nikolaus Plesnila; Antonis K Hatzopoulos
Journal:  Am J Pathol       Date:  2008-06-13       Impact factor: 4.307

8.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

9.  MoonProt: a database for proteins that are known to moonlight.

Authors:  Mathew Mani; Chang Chen; Vaishak Amblee; Haipeng Liu; Tanu Mathur; Grant Zwicke; Shadi Zabad; Bansi Patel; Jagravi Thakkar; Constance J Jeffery
Journal:  Nucleic Acids Res       Date:  2014-10-16       Impact factor: 16.971

10.  Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.

Authors:  Deepika Dhawan; Melissa Paoloni; Shweta Shukradas; Dipanwita Roy Choudhury; Bruce A Craig; José A Ramos-Vara; Noah Hahn; Patty L Bonney; Chand Khanna; Deborah W Knapp
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

View more
  3 in total

1.  Bioinformatics Analysis of Gene Expression Profiles of Sex Differences in Ischemic Stroke.

Authors:  Wenhao Zhu; Yinan Nan; Shaoqing Wang; Wei Liu
Journal:  Biomed Res Int       Date:  2019-04-30       Impact factor: 3.411

2.  Identification of a ferroptosis-related gene pair biomarker with immune infiltration landscapes in ischemic stroke: a bioinformatics-based comprehensive study.

Authors:  Jiaxin Fan; Mengying Chen; Shuai Cao; Qingling Yao; Xiaodong Zhang; Shuang Du; Huiyang Qu; Yuxuan Cheng; Shuyin Ma; Meijuan Zhang; Yizhou Huang; Nan Zhang; Kaili Shi; Shuqin Zhan
Journal:  BMC Genomics       Date:  2022-01-16       Impact factor: 3.969

3.  Genome-Wide Association Study of the Relationship Between Matrix Metalloproteinases and Intracranial Aneurysms.

Authors:  Bong Jun Kim; Eun Pyo Hong; Dong Hyuk Youn; Jin Pyeong Jeon
Journal:  J Clin Neurol       Date:  2022-02-14       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.